• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

紫草素通过内质网介导的抗肿瘤作用对乳腺癌的影响。

ER-mediated anti-tumor effects of shikonin on breast cancer.

机构信息

School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.

School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, 100029, China.

出版信息

Eur J Pharmacol. 2019 Nov 15;863:172667. doi: 10.1016/j.ejphar.2019.172667. Epub 2019 Sep 20.

DOI:10.1016/j.ejphar.2019.172667
PMID:31545985
Abstract

Estrogen receptor (ER) is expressed in most Breast cancer (BC) patients. G protein-coupled estrogen receptor (GPER), which is a membrane-bound estrogen receptor, is associated with the tumor development and progression in BC. Shikonin (SK) is a natural compound that is known to have anti-tumor effects. This study aims to assess the effects of shikonin on the cell proliferation, cell cycle and cell apoptosis of BC and whether the effects are related to ER/GPER signaling pathway. The results demonstrated that shikonin inhibited the cellular proliferation of MCF-7 BC cells via G/G arrest and apoptosis in concentration-dependent manner. The anti-proliferative effect of SK on SK-BR-3 BC cells was associated with apoptosis. Both ERα and GPER were expressed in MCF-7 cells, while ERα were negative and GPER were positive in SK-BR-3 cells. Furthermore, shikonin downregulated the expression of ERα and GPER, and this effect was not affected by the estrogen environment. In addition, shikonin downregulated the EGFR and p-ERK expression in MCF-7 and SK-BR-3, which was also not affected by the estrogen environment. EGFR and p-ERK were still suppressed by co-treatment with the selective GPER against G1 or antagonist G15. In conclusion, these results suggest that shikonin shows anti-tumor effects on MCF-7 and SK-BR-3 cells. The effects seem to be associated with EGFR/p-ERK downregulation via ERα and GPER inhibition.

摘要

雌激素受体 (ER) 在大多数乳腺癌 (BC) 患者中表达。G 蛋白偶联雌激素受体 (GPER) 是一种膜结合型雌激素受体,与 BC 中的肿瘤发生和进展有关。紫草素 (SK) 是一种天然化合物,已知具有抗肿瘤作用。本研究旨在评估紫草素对 BC 细胞增殖、细胞周期和细胞凋亡的影响,以及这些作用是否与 ER/GPER 信号通路有关。结果表明,紫草素通过 G1 期阻滞和凋亡,呈浓度依赖性抑制 MCF-7 BC 细胞的增殖。SK 对 SK-BR-3 BC 细胞的抗增殖作用与凋亡有关。ERα和 GPER 在 MCF-7 细胞中均有表达,而 ERα在 SK-BR-3 细胞中为阴性,GPER 为阳性。此外,紫草素下调 ERα和 GPER 的表达,这种作用不受雌激素环境的影响。此外,紫草素下调 MCF-7 和 SK-BR-3 中 EGFR 和 p-ERK 的表达,这种作用也不受雌激素环境的影响。用选择性 GPER 针对 G1 或拮抗剂 G15 共同处理,仍能抑制 EGFR 和 p-ERK。综上所述,这些结果表明紫草素对 MCF-7 和 SK-BR-3 细胞具有抗肿瘤作用。这些作用似乎与通过 ERα和 GPER 抑制下调 EGFR/p-ERK 有关。

相似文献

1
ER-mediated anti-tumor effects of shikonin on breast cancer.紫草素通过内质网介导的抗肿瘤作用对乳腺癌的影响。
Eur J Pharmacol. 2019 Nov 15;863:172667. doi: 10.1016/j.ejphar.2019.172667. Epub 2019 Sep 20.
2
Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER.G蛋白偶联雌激素受体GPER介导雌激素对FOXO3a的失活作用。
BMC Cancer. 2015 Oct 15;15:702. doi: 10.1186/s12885-015-1699-6.
3
Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.苯并吡喃衍生物 CDRI-85/287 通过调节雌激素受体 α 和 β 介导的信号,与 EGFR 信号平行,诱导雌激素受体阳性乳腺癌细胞的 G2-M 期阻滞,并抑制肿瘤异种移植物的生长。
Steroids. 2013 Nov;78(11):1071-86. doi: 10.1016/j.steroids.2013.07.004. Epub 2013 Jul 26.
4
MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.MIBE 在乳腺癌细胞中作为雌激素受体 α 和 GPER 的拮抗剂配体发挥作用。
Breast Cancer Res. 2012 Jan 17;14(1):R12. doi: 10.1186/bcr3096.
5
Bisphenol AF exerts estrogenic activity in MCF-7 cells through activation of Erk and PI3K/Akt signals via GPER signaling pathway.双酚 AF 通过 GPER 信号通路激活 Erk 和 PI3K/Akt 信号,在 MCF-7 细胞中发挥雌激素活性。
Chemosphere. 2019 Apr;220:362-370. doi: 10.1016/j.chemosphere.2018.12.122. Epub 2018 Dec 24.
6
Targeting Cell Necroptosis and Apoptosis Induced by Shikonin via Receptor Interacting Protein Kinases in Estrogen Receptor Positive Breast Cancer Cell Line, MCF-7.通过受体相互作用蛋白激酶靶向紫草素诱导雌激素受体阳性乳腺癌细胞系MCF-7中的细胞坏死性凋亡和凋亡
Anticancer Agents Med Chem. 2018;18(2):245-254. doi: 10.2174/1871520617666170919164055.
7
Identification of Breast Cancer Inhibitors Specific for G Protein-Coupled Estrogen Receptor (GPER)-Expressing Cells.鉴定针对表达G蛋白偶联雌激素受体(GPER)的细胞的乳腺癌抑制剂。
ChemMedChem. 2017 Aug 22;12(16):1279-1285. doi: 10.1002/cmdc.201700145. Epub 2017 Jun 20.
8
GPER functions as a tumor suppressor in MCF-7 and SK-BR-3 breast cancer cells.G 蛋白偶联雌激素受体在 MCF-7 和 SK-BR-3 乳腺癌细胞中作为肿瘤抑制因子发挥作用。
J Cancer Res Clin Oncol. 2014 Apr;140(4):663-71. doi: 10.1007/s00432-014-1598-2. Epub 2014 Feb 11.
9
Estrogen receptor α dependent regulation of estrogen related receptor β and its role in cell cycle in breast cancer.雌激素受体α依赖性调节雌激素相关受体β及其在乳腺癌细胞周期中的作用。
BMC Cancer. 2018 May 30;18(1):607. doi: 10.1186/s12885-018-4528-x.
10
NDV-D90 inhibits 17β-estradiol-mediated resistance to apoptosis by differentially modulating classic and nonclassic estrogen receptors in breast cancer cells.新城疫病毒D90通过差异性调节乳腺癌细胞中的经典和非经典雌激素受体,抑制17β-雌二醇介导的细胞凋亡抗性。
J Cell Biochem. 2021 Jan;122(1):3-15. doi: 10.1002/jcb.28118. Epub 2020 Sep 28.

引用本文的文献

1
Traditional Chinese medicine in the treatment of breast Cancer.中医治疗乳腺癌
Mol Cancer. 2025 Aug 1;24(1):209. doi: 10.1186/s12943-025-02416-5.
2
Review projecting shikonin as a therapeutic candidate in female carcinomas: a preclinical perspective.展望紫草素作为女性癌症治疗候选药物:临床前视角
Front Pharmacol. 2025 Jul 4;16:1627124. doi: 10.3389/fphar.2025.1627124. eCollection 2025.
3
Synergistic Effect of Ribitol and Shikonin Promotes Apoptosis in Breast Cancer Cells.核糖醇与紫草素的协同作用促进乳腺癌细胞凋亡。
Int J Mol Sci. 2025 Mar 15;26(6):2661. doi: 10.3390/ijms26062661.
4
Natural Shikonin Potentially Alters Intestinal Flora to Alleviate Acute Inflammation.天然紫草素可能通过改变肠道菌群来减轻急性炎症。
Microorganisms. 2023 Aug 23;11(9):2139. doi: 10.3390/microorganisms11092139.
5
Promising Nanomedicines of Shikonin for Cancer Therapy.紫草素在癌症治疗中的有前景的纳米药物。
Int J Nanomedicine. 2023 Mar 10;18:1195-1218. doi: 10.2147/IJN.S401570. eCollection 2023.
6
Screening and characterization estrogen receptor ligands from (Royle) Johnst. affinity ultrafiltration LC-MS and molecular docking.基于(罗伊尔)约翰斯亲和超滤液相色谱-质谱联用及分子对接技术筛选和表征雌激素受体配体。
Front Plant Sci. 2022 Nov 7;13:1012553. doi: 10.3389/fpls.2022.1012553. eCollection 2022.
7
Pharmacological and analytical aspects of alkannin/shikonin and their derivatives: An update from 2008 to 2022.紫朱草素/紫草素及其衍生物的药理学与分析学研究进展:2008年至2022年最新情况
Chin Herb Med. 2022 Sep 20;14(4):511-527. doi: 10.1016/j.chmed.2022.08.001. eCollection 2022 Oct.
8
Shikonin Mediates Apoptosis through G Protein-Coupled Estrogen Receptor of Ovarian Cancer Cells.紫草素通过卵巢癌细胞的G蛋白偶联雌激素受体介导细胞凋亡。
Evid Based Complement Alternat Med. 2022 Oct 5;2022:6517732. doi: 10.1155/2022/6517732. eCollection 2022.
9
Herbal Ingredients in the Prevention of Breast Cancer: Comprehensive Review of Potential Molecular Targets and Role of Natural Products.草药成分在预防乳腺癌中的作用:对潜在分子靶点和天然产物作用的综合综述。
Oxid Med Cell Longev. 2022 Aug 16;2022:6044640. doi: 10.1155/2022/6044640. eCollection 2022.
10
Review of Shikonin and Derivatives: Isolation, Chemistry, Biosynthesis, Pharmacology and Toxicology.紫草素及其衍生物综述:分离、化学、生物合成、药理学与毒理学
Front Pharmacol. 2022 Jul 1;13:905755. doi: 10.3389/fphar.2022.905755. eCollection 2022.